Please login to the form below

Not currently logged in
Email:
Password:

Pfizer halts development of lung cancer drug

Pfizer has halted a development programme in lung cancer for investigational toll-like receptor agonist, PF-3512676, in combination with cytotoxic chemotherapy.

Pfizer has halted a development programme in lung cancer for investigational toll-like receptor agonist, PF-3512676, in combination with cytotoxic chemotherapy.

Pfizer licensed PF- 3512676 from Coley Pharmaceutical in 2005 and the discontinuation included two phase III clinical trials and two phase II clinical trials. 

A interim analysis of the phase III clinical trials by an independent Data Safety Monitoring Committee (DSMC) showed there was no evidence that PF-3512676 produced additional clinical efficacy over that achieved with the standard cytotoxic chemotherapy regimen alone. The DSMC concluded that the risk-benefit profile did not justify continuation of the trials. Pfizer agreed with the findings and put a stop to the related clinical trials.

Dr Charles Baum, who is vice-president of Pfizer's R&D, said: "We are communicating these results to patients and the scientific and medical community. While these results show the challenge of bringing new therapies to patients with cancer, Pfizer remains committed to advancing our broad and diverse oncology programs which include over two hundred clinical trials of sixteen new medicines in clinical studies in immunotherapy, signal transduction inhibition and angiogenesis inhibition."

Pfizer shares fell USD 0.34 cents to rest at USD 25.87 in recent trading.

PF-3512676 was not seen as a major potential earner for Pfizer, with Bear Stearns analysts forecasting sales of USD 384m in 2010 had it reached market.

The impact of the discontinuation on co-development partner, Coley Pharmaceutical, a small US-based drug-development company was far more severe. The compound had been Coley's most advanced pipeline candidate, and the company would have earned significant royalty revenue from product sales. Coley shares dropped 56 per cent to USD 3.71 in recent trading.

Coley said in a press statement that the discontinuation of PF-3512676 was surprising, because it showed signs of activity in a smaller, mid-stage trial.

 

22nd June 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics